Month: May 2025

IRADIMED CORPORATION Announces First Quarter 2025 Financial Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Announces Regular Quarterly Cash Dividend of $0.17 Per Share Reaffirms Full Year 2025 Revenue and Earnings GuidanceReports record revenue of $19.5 million for the first quarter of 2025, an increase of $1.9 million or 11%, compared to the same period in 2024.Reports GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42 for the first quarter of 2025, which are increases of 16% and 17%, respectively, compared to the same period in 2024.Declares a regular quarterly cash dividend of $0.17 per common share for the second quarter of 2025, payable on May 30, 2025.WINTER SPRINGS, Fla., May 05, 2025 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months ended March 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging...

Quantum Biopharma Files Amended Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Written by Customer Service on May 5, 2025. Posted in Public Companies.

To assist enquiries a copy of the amended complaint can be viewed by clicking the following link:Quantum Amended Court Claim TORONTO, May 05, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that on May 1, 2025 it filed an amended complaint in the United States District Court for the Southern District of New York. This is an amendment to the original complaint filed on October 21, 2024, is in response to the Motion to Dismiss filed by the banks on January 31, 2025, and is filed in the United States District Court for the Southern District of New York. The amendment and complaint allege that CIBC World Markets (CIBC), RBC Dominion Securities...

Goliath Resources Engages JDS Energy & Mining Inc. To Forge Plans To Drive An Exploration Adit At Its Surebet Discovery, Golddigger Property, Golden Triangle, B.C.

Written by Customer Service on May 5, 2025. Posted in Public Companies.

Drill-out of all high-grade Surebet lodes will be more easily and cheaply facilitated from underground vantages. Underground access to the Bonanza Zone will enable geological confirmation of this important high-grade lode and potentially enable bulk sampling. Goliath looks forward to mobilizing shortly for its aggressive 2025 drill campaign.TORONTO, May 05, 2025 (GLOBE NEWSWIRE) — Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (FSE: B4IF) (the “Company” or “Goliath”) is pleased to announce world renowned JDS Energy & Mining Inc. (“JDS”) has been engaged to assess the viability, permitting and development of an underground exploration adit at Surebet, at its 100% controlled Golddigger property (the “Property”), Golden Triangle, British Columbia. The Company has tasked JDS with an exploration adit to access a broad...

USA Rare Earth Announces Closing of $75 Million PIPE Financing

Written by Customer Service on May 5, 2025. Posted in Public Companies.

STILLWATER, Okla., May 05, 2025 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company), today announced the closing of its previously announced private investment in public equity (PIPE) financing. The PIPE is with a single institutional investor for total gross proceeds of $75 million. The Company intends to use the proceeds from the offering to fund capital expenditures for its magnet manufacturing facility in Stillwater, Oklahoma, as well as for working capital and operating expenses. Cantor Fitzgerald & Co. acted as lead placement agent for the private placement and Cohen Capital Markets also acted as placement agent. Roth Capital Partners, LLC and Jett Capital Advisors, LLC also acted as advisors to the Company on the transaction. White & Case LLP served as legal counsel to USA Rare Earth. Reed...

Integra LifeSciences Reports First Quarter 2025 Financial Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 HighlightsFirst quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year.First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact related to the new tariffs.“We remain laser focused on strengthening our quality systems, improving supply reliability, and driving operational...

Freshpet, Inc. Reports First Quarter 2025 Financial Results

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Delivers Approximately 18% Net Sales GrowthStrong Operating Performance on Input, Quality and Logistics CostsUpdates 2025 Outlook BEDMINSTER, N.J., May 05, 2025 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Compared to Prior Year PeriodNet sales of $263.2 million, an increase of 17.6%. Net loss of $12.7 million, compared to the prior year period net income of $18.6 million. Gross margin of 39.4%, consistent with the prior year period of 39.4%. Adjusted Gross Margin of 45.7%, compared to the prior year period of 45.3%.1 Adjusted EBITDA of $35.5 million, compared to the prior year period of $30.6 million.1“Despite the recent macro-economic headwinds, we believe Freshpet remains...

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapiesPresented multiple clinical updates across oncology pipeline underlining BioNTech’s combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”)Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccineFirst quarter 2025 revenues of €0.2 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823)Maintained strong financial position with €15.9 billion in cash, cash equivalents and security investments as of March 31, 20254Full year 2025 financial guidance confirmedConference...

CORRECTION: Oma Savings Bank Plc’s Interim Report 1.1.-31.3.2025: High costs and declining market interest rates weighed on the result, work to strengthen OmaSp continues

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 5 MAY 2025 AT 13.00 A.M. EET, INTERIM REPORT Q1 CORRECTION: Oma Savings Bank Plc’s Interim Report 1.1.-31.3.2025: High costs and declining market interest rates weighed on the result, work to strengthen OmaSp continues This release corrects the January-March interim report published today at 9.45 a.m. EET. The CEO’s review contained an incorrect figure regarding the total investments in the Noste project. The corrected sentence reads: Total investments in the Noste project reached EUR 11.6 million over its duration. Below the corrected stock exchange release and the interim report January-March 2025 attached. Oma Savings Bank Plc’s Interim Report 1.1.-31.3.2025: High costs and declining market interest rates weighed on the result, work to strengthen OmaSp continues This release is a summary...

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on May 5, 2025. Posted in Earnings Releases And Operating Results.

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven review Partnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseases Platform and Operations: Implemented meaningful synergies and streamlined operations while maintaining capabilities, resulting in cash runway until mid 2027SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results...

RetinalGenix Technologies, Inc. Announces Laboratory Lease Agreement with Life Science Incubator MBC BioLabs

Written by Customer Service on May 5, 2025. Posted in Public Companies.

Company to use facility to further development of RetinalGenix’s therapies for neurodegenerative and retinal diseases APOLLO BEACH, Fla., May 05, 2025 (GLOBE NEWSWIRE) — RetinalGenix Technologies, Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), announced today a new laboratory lease agreement with life science incubator MBC BioLabs for a brand new facility located in San Carlos, California. The lease includes an option for Mission BioCapital, an affiliate of MBC Biolabs, to potentially invest in RetinalGenix. The Company plans to use the facility to further the development of its RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. The fully equipped laboratory space provides access to world-class scientific equipment, including incubators, centrifuges, freeze dryers, and mass spectrometers. The lab is strategically...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals